Next Article in Journal
Slower Elimination of Tofacitinib in Acute Renal Failure Rat Models: Contribution of Hepatic Metabolism and Renal Excretion
Next Article in Special Issue
Subset Analysis for Screening Drug–Drug Interaction Signal Using Pharmacovigilance Database
Previous Article in Journal
Formulation and Characterisation of a Combination Captopril and Hydrochlorothiazide Microparticulate Dosage Form
Previous Article in Special Issue
Effect of Rumex Acetosa Extract, a Herbal Drug, on the Absorption of Fexofenadine
 
 
Article

Prevalence of Potential Drug–Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital

1
Biosanitary Research Institute of Extremadura (INUBE), University of Extremadura, 06006 Badajoz, Spain
2
Department of Nursing, University of Extremadura, 10600 Plasencia, Spain
3
Nephrology Department, Virgen del Puerto Hospital, Servicio Extremeño de Salud, 10600 Plasencia, Spain
4
Department of Anatomy, Cellular Biology and Zoology, University of Extremadura, 10600 Plasencia, Spain
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(8), 713; https://doi.org/10.3390/pharmaceutics12080713
Received: 30 June 2020 / Revised: 17 July 2020 / Accepted: 28 July 2020 / Published: 30 July 2020
(This article belongs to the Special Issue Drug–Drug Interactions)
Chronic kidney disease (CKD) is a major health problem worldwide and, in Spain, it is present in 15.1% of individuals. CKD is frequently associated with some comorbidities and patients need to be prescribed multiple medications. Polypharmacy increases the risk of adverse drug reactions (ADRs). There are no published studies evaluating the prevalence of potential drug–drug interactions (pDDIs) among CKD patients in any European country. This study was aimed to determine the prevalence, pattern, and factors associated with pDDIs among CKD patients using a drug interactions program. An observational cross-sectional study was carried out at Plasencia Hospital, located in Spain. Data were collected among patients with CKD diagnoses and pDDIs were assessed by the Lexicomp® Drug Interactions platform. Data were obtained from 112 CKD patients. A total number of 957 prescribed medications were acknowledged, and 928 pDDIs were identified in 91% of patients. Age and concomitant drugs were significantly associated with the number of pDDIs (p < 0.05). According to the results, the use of programs for the determination of pDDIs (such as Lexicomp®) is recommended in the clinical practice of CKD patients in order to avoid serious adverse effects, as is paying attention to contraindicated drug combinations. View Full-Text
Keywords: chronic kidney disease; drug–drug interactions; polypharmacy; adverse drug reactions; Lexicomp chronic kidney disease; drug–drug interactions; polypharmacy; adverse drug reactions; Lexicomp
Show Figures

Figure 1

MDPI and ACS Style

Santos-Díaz, G.; Pérez-Pico, A.M.; Suárez-Santisteban, M.Á.; García-Bernalt, V.; Mayordomo, R.; Dorado, P. Prevalence of Potential Drug–Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital. Pharmaceutics 2020, 12, 713. https://doi.org/10.3390/pharmaceutics12080713

AMA Style

Santos-Díaz G, Pérez-Pico AM, Suárez-Santisteban MÁ, García-Bernalt V, Mayordomo R, Dorado P. Prevalence of Potential Drug–Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital. Pharmaceutics. 2020; 12(8):713. https://doi.org/10.3390/pharmaceutics12080713

Chicago/Turabian Style

Santos-Díaz, Gracia, Ana María Pérez-Pico, Miguel Ángel Suárez-Santisteban, Vanesa García-Bernalt, Raquel Mayordomo, and Pedro Dorado. 2020. "Prevalence of Potential Drug–Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital" Pharmaceutics 12, no. 8: 713. https://doi.org/10.3390/pharmaceutics12080713

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop